Singapore | Imports and Exports | World | Pharmaceutical products | Value (US$) and Value Growth, YoY (%) | 2012 - 2023
The value of exports of commodity group 30 "Pharmaceutical products" from Singapore totalled $ 11 billion in 2023. Sales of commodity group 30 from Singapore went up by 12.1% compared to 2022: exports of commodity group 30 "Pharmaceutical products" went up by $ 1.19 billion (cumulative exports of commodity group 30 from Singapore amounted $9.84 billion in 2022)
Exports of commodity group 30 "Pharmaceutical products" amounted to 2.32% of total exports from Singapore (cumulative merchandise exports from Singapore totalled $ 475 billion in 2023). The share of commodity group 30 in total exports from Singapore increased by 0.411 p.p. compared to 2022 (it was 1.91% in 2022 and cumulative exports from Singapore were equal to $ 514 billion).
Where does Singapore export Pharmaceutical products?
Top export destinations of "Pharmaceutical products" from Singapore in 2023:
- Switzerland with a share of 22% (2.45 billion US$)
- China with a share of 21% (2.31 billion US$)
- USA with a share of 11.7% (1.29 billion US$)
- Japan with a share of 10% (1.1 billion US$)
- Netherlands with a share of 4.22% (466 million US$)
- Belgium with a share of 4.09% (451 million US$)
- Korea with a share of 2.59% (286 million US$)
- Other Asia, nes with a share of 2.49% (274 million US$)
- France with a share of 2.48% (274 million US$)
- Hong Kong with a share of 2.44% (270 million US$)
Exports structure of 30 - Pharmaceutical products - from Singapore in 2023 represented by the following main commodity groups:
- 46% (5.07 billion US$): 3004 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale
- 41% (4.62 billion US$): 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc
- 5.15% (569 million US$): 3001 - Glands, organs (extracts, secretions thereof) for organo-therapeutic uses, dried, powdered or not; heparin and its salts; other human or animal substances for therapeutic or prophylactic uses n.e.s.
- 3.95% (436 million US$): 3003 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale
- 1.7% (188 million US$): 3006 - Pharmaceutical goods specified in Note 4 to this Chapter.
- 1.29% (143 million US$): 3005 - Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes.
The value of imports of commodity group 30 "Pharmaceutical products" to Singapore totalled $ 4.35 billion in 2023. Sales of commodity group 30 to Singapore decreased by 15.9% in value terms compared to 2022. imports of commodity group 30 "Pharmaceutical products" decreased by $ 828 million (the value of imports of commodity group 30 to Singapore was equal to $5.18 billion in 2022)
Imports of commodity group 30 "Pharmaceutical products" accounted for 1.03% of total import flow to Singapore (in 2023, total imports to Singapore amounted to $ 422 billion). The share of commodity group 30 in total imports to Singapore decreased by 0.059 p.p. compared to 2022 (it was 1.08% in 2022 and cumulative imports to Singapore were equal to $ 475 billion).
Where does Singapore import Pharmaceutical products from?
Top trading partners (import of "Pharmaceutical products") of Singapore in 2023:
- USA with a share of 16.4% (714 million US$)
- France with a share of 15.6% (680 million US$)
- Germany with a share of 11.7% (509 million US$)
- Ireland with a share of 11% (482 million US$)
- Spain with a share of 6.55% (285 million US$)
- Switzerland with a share of 5.66% (246 million US$)
- Belgium with a share of 3.27% (142 million US$)
- Sweden with a share of 2.94% (127 million US$)
- Italy with a share of 2.58% (112 million US$)
- China with a share of 2.35% (102 million US$)
Imports structure of 30 - Pharmaceutical products - to Singapore in 2023 represented by the following main commodity groups:
- 43% (1.91 billion US$): 3004 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses (including those in the form of transdermal administration systems) or in forms or packings for retail sale
- 33% (1.46 billion US$): 3002 - Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc
- 11.9% (521 million US$): 3001 - Glands, organs (extracts, secretions thereof) for organo-therapeutic uses, dried, powdered or not; heparin and its salts; other human or animal substances for therapeutic or prophylactic uses n.e.s.
- 7.74% (336 million US$): 3006 - Pharmaceutical goods specified in Note 4 to this Chapter.
- 2.43% (105 million US$): 3005 - Wadding, gauze, bandages and similar articles (for example, dressings, adhesive plasters, poultices), impregnated or coated with pharmaceutical substances or put up in forms or packings for retail sale for medical, surgical, dental or veterinary purposes.
- 0.211% (9.22 million US$): 3003 - Medicaments (excluding goods of heading 30.02, 30.05 or 30.06) consisting of two or more constituents which have been mixed together for therapeutic or prophylactic uses, not put up in measured doses or in forms or packings for retail sale
